Yahoo
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation. In follow-up to the successful Type B meeting in e
Yahoo
Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L) for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity […]
Yahoo
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-
Yahoo
Mesoblast (ASX:MSB) experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific...
Yahoo
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not
SeekingAlpha
Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SHCO | 45.45% | $1.49B | +40.11% | 0.00% |
| ACN | 34.90% | $205.89B | -0.40% | 1.90% |
| DRI | 34.25% | $25.70B | +49.62% | 2.58% |
| BNT | 33.52% | $12.45B | +48.00% | 0.00% |
| TRIP | 33.46% | $1.82B | -21.77% | 0.00% |
| FSK | 33.26% | - | - | 12.12% |
| OBDC | 32.77% | $7.35B | -6.59% | 10.26% |
| AMZN | 32.33% | $2.34T | +10.23% | 0.00% |
| GLAD | 32.21% | - | - | 7.30% |
| PSNL | 32.04% | $580.30M | +447.50% | 0.00% |
| BN | 31.96% | $102.15B | +47.36% | 0.55% |
| VERI | 31.85% | $65.48M | -39.91% | 0.00% |
| PRTA | 31.83% | $336.96M | -69.30% | 0.00% |
| MAIN | 31.57% | $5.28B | +17.86% | 5.01% |
| J | 31.49% | $15.92B | +16.51% | 0.93% |
| FDS | 31.01% | $17.09B | +8.24% | 0.94% |
| TSEM | 30.78% | $4.74B | +7.80% | 0.00% |
| BLX | 30.52% | $1.49B | +31.32% | 5.55% |
| NTRA | 30.44% | $21.95B | +45.19% | 0.00% |
| META | 30.30% | $1.81T | +41.16% | 0.29% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -12.42% | $24.29B | +35.36% | 1.09% |
| GFI | -11.48% | $21.24B | +58.84% | 2.32% |
| K | -10.50% | $27.71B | +40.85% | 2.85% |
| BCE | -9.73% | $20.86B | -27.77% | 10.84% |
| PPC | -8.81% | $10.79B | +32.45% | 0.00% |
| BTI | -8.69% | $102.21B | +50.27% | 6.54% |
| PHYS.U | -8.37% | - | - | 0.00% |
| WHWK | -8.30% | $87.62M | +40.91% | 0.00% |
| NOC | -8.20% | $72.47B | +15.13% | 1.72% |
| LTM | -8.19% | $12.31B | -95.54% | 2.46% |
| ASPS | -8.14% | $99.18M | -12.89% | 0.00% |
| TPIC | -8.13% | $43.34M | -74.91% | 0.00% |
| AMT | -7.87% | $105.08B | +16.75% | 2.96% |
| MO | -7.87% | $97.93B | +26.25% | 6.95% |
| ED | -7.86% | $36.31B | +13.27% | 3.35% |
| MDLZ | -7.71% | $89.29B | +4.44% | 2.72% |
| SAVA | -7.23% | $89.37M | -84.31% | 0.00% |
| AGL | -7.18% | $985.21M | -59.52% | 0.00% |
| MSEX | -6.85% | $1.01B | +5.19% | 2.41% |
| MVO | -6.65% | $66.70M | -38.30% | 21.83% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -32.40% | $99.49M | 0.59% |
| VIXY | -26.04% | $165.58M | 0.85% |
| FXY | -24.68% | $820.31M | 0.4% |
| BTAL | -17.84% | $295.67M | 1.43% |
| FTSD | -17.56% | $231.68M | 0.25% |
| IVOL | -16.75% | $348.25M | 1.02% |
| XONE | -13.16% | $585.85M | 0.03% |
| IBTG | -12.30% | $1.92B | 0.07% |
| SPTS | -11.30% | $5.77B | 0.03% |
| UTWO | -10.61% | $379.27M | 0.15% |
| IBTI | -10.60% | $1.06B | 0.07% |
| UDN | -10.36% | $147.49M | 0.78% |
| STPZ | -10.04% | $450.05M | 0.2% |
| IBTK | -9.87% | $441.97M | 0.07% |
| FXE | -9.54% | $578.76M | 0.4% |
| IBTJ | -9.20% | $684.86M | 0.07% |
| BWX | -9.19% | $1.53B | 0.35% |
| XHLF | -9.09% | $1.73B | 0.03% |
| GOVT | -8.62% | $27.46B | 0.05% |
| SMMU | -8.54% | $889.48M | 0.35% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PAPR | 33.92% | $844.25M | 0.79% |
| PSFF | 33.75% | $479.95M | 0.75% |
| PNQI | 33.48% | $775.63M | 0.6% |
| USMC | 33.38% | $3.24B | 0.12% |
| BUFG | 33.32% | $264.90M | 1.05% |
| BJUN | 33.13% | $158.16M | 0.79% |
| PMAR | 33.09% | $667.45M | 0.79% |
| QLTY | 33.03% | $1.99B | 0.5% |
| FTQI | 32.98% | $623.04M | 0.76% |
| OEF | 32.98% | $20.46B | 0.2% |
| FFEB | 32.93% | $1.05B | 0.85% |
| UFEB | 32.92% | $264.24M | 0.79% |
| FCOM | 32.91% | $1.61B | 0.084% |
| FFLC | 32.91% | $768.12M | 0.38% |
| ZALT | 32.86% | $480.58M | 0.69% |
| PJUL | 32.79% | $904.08M | 0.79% |
| PJUN | 32.77% | $723.22M | 0.79% |
| BUFQ | 32.67% | $991.41M | 1% |
| UJAN | 32.61% | $261.30M | 0.79% |
| PSTP | 32.58% | $114.26M | 0.89% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| JUCY | 0.02% | $269.60M | 0.6% |
| CGMU | -0.02% | $3.36B | 0.27% |
| BAB | 0.02% | $928.24M | 0.28% |
| FISR | 0.07% | $428.82M | 0.5% |
| BNDW | 0.21% | $1.28B | 0.05% |
| VCRB | -0.23% | $3.12B | 0.1% |
| SCHZ | -0.26% | $8.56B | 0.03% |
| STOT | 0.28% | $253.88M | 0.45% |
| LMBS | 0.32% | $5.10B | 0.64% |
| GLTR | 0.38% | $1.43B | 0.6% |
| KCCA | 0.39% | $105.90M | 0.87% |
| IBDW | 0.39% | $1.57B | 0.1% |
| BBAG | -0.40% | $1.28B | 0.03% |
| FXB | -0.41% | $92.39M | 0.4% |
| UITB | -0.44% | $2.33B | 0.39% |
| LTPZ | -0.57% | $669.63M | 0.2% |
| IBMR | 0.59% | $255.40M | 0.18% |
| FMHI | -0.60% | $753.22M | 0.7% |
| MLN | 0.62% | $540.39M | 0.24% |
| GSST | 0.63% | $919.83M | 0.16% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACIC | -0.02% | $531.89M | +7.78% | 0.00% |
| YORW | -0.05% | $465.42M | -13.07% | 2.67% |
| GILD | 0.14% | $138.98B | +63.35% | 2.80% |
| SPRY | 0.16% | $1.58B | +85.80% | 0.00% |
| HLN | 0.19% | $46.54B | +24.25% | 1.73% |
| GHI | 0.19% | $264.16M | -23.09% | 12.49% |
| LITB | -0.20% | $22.07M | -77.41% | 0.00% |
| RGR | 0.23% | $597.47M | -12.55% | 1.99% |
| LHX | 0.26% | $47.14B | +12.78% | 1.89% |
| GO | 0.27% | $1.27B | -41.23% | 0.00% |
| RKT | 0.27% | $2.19B | +14.88% | 0.00% |
| BGS | 0.32% | $354.30M | -43.87% | 16.96% |
| KGC | 0.33% | $19.05B | +93.64% | 0.77% |
| CIG.C | -0.37% | $2.64B | +29.74% | 0.00% |
| HUSA | -0.37% | $21.26M | -8.69% | 0.00% |
| HAIN | -0.37% | $149.82M | -76.12% | 0.00% |
| PLCE | -0.41% | $94.88M | -44.49% | 0.00% |
| TKC | 0.42% | $5.42B | -18.59% | 5.18% |
| SDHC | 0.45% | $182.53M | -5.54% | 0.00% |
| JNJ | 0.49% | $375.15B | +6.77% | 3.23% |
Current Value
$10.991 Year Return
Current Value
$10.991 Year Return
